<DOC>
	<DOCNO>NCT01431833</DOCNO>
	<brief_summary>Assess single dose PK safety TR701 FA subject Moderate Severe hepatic impairment versus match control subject normal hepatic function .</brief_summary>
	<brief_title>A PK Safety Study Subjects With Hepatic Impairment</brief_title>
	<detailed_description>This study assess single-dose pharmacokinetics ( PK ) safety TR-701 free acid ( FA ) subject Moderate Severe hepatic impairment compare match control subject normal hepatic function .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Moderate severe hepatic impairment match control BMI 18.0 40.0 kg/m2 Evidence acute deterioration hepatic function within 8 week ALT AST ≥ 5 time upper limit normal moderate ; ALT AST ≥ 8 time upper limit normal severes Total bilirubin &gt; 5 mg/dl moderate ; upper limit severes Hemoglobin &lt; 10g/dl moderate ; Hemoglobin &lt; 9g/dl severes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Matched control subject</keyword>
</DOC>